AR124604A1 - Mutantes de fimh, composiciones con los mismos y uso de los mismos - Google Patents
Mutantes de fimh, composiciones con los mismos y uso de los mismosInfo
- Publication number
- AR124604A1 AR124604A1 ARP220100049A ARP220100049A AR124604A1 AR 124604 A1 AR124604 A1 AR 124604A1 AR P220100049 A ARP220100049 A AR P220100049A AR P220100049 A ARP220100049 A AR P220100049A AR 124604 A1 AR124604 A1 AR 124604A1
- Authority
- AR
- Argentina
- Prior art keywords
- fimh
- lectin domain
- compositions
- mutants
- polypeptides
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000004856 Lectins Human genes 0.000 abstract 3
- 108090001090 Lectins Proteins 0.000 abstract 3
- 239000002523 lectin Substances 0.000 abstract 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21151126 | 2021-01-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124604A1 true AR124604A1 (es) | 2023-04-12 |
Family
ID=74175646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100049A AR124604A1 (es) | 2021-01-12 | 2022-01-11 | Mutantes de fimh, composiciones con los mismos y uso de los mismos |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11725028B2 (https=) |
| EP (1) | EP4277921A1 (https=) |
| JP (2) | JP7532672B2 (https=) |
| KR (2) | KR20250007029A (https=) |
| CN (1) | CN116888140A (https=) |
| AR (1) | AR124604A1 (https=) |
| AU (1) | AU2022207740B2 (https=) |
| CA (1) | CA3207841A1 (https=) |
| IL (1) | IL303954B2 (https=) |
| MX (1) | MX2023008251A (https=) |
| TW (1) | TW202241929A (https=) |
| WO (1) | WO2022153166A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4461744A3 (en) | 2020-01-16 | 2025-01-08 | Janssen Pharmaceuticals, Inc. | Fimh mutant, compositions therewith and use thereof |
| KR20250007029A (ko) | 2021-01-12 | 2025-01-13 | 얀센 파마슈티칼즈, 인코포레이티드 | FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도 |
| PE20241621A1 (es) * | 2021-12-17 | 2024-08-07 | Pfizer | Composiciones de polinucleotidos y sus usos |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4987237A (en) | 1983-08-26 | 1991-01-22 | Ribi Immunochem Research, Inc. | Derivatives of monophosphoryl lipid A |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| JPH0655749B2 (ja) | 1989-09-20 | 1994-07-27 | 日本たばこ産業株式会社 | リピッドａ単糖類縁体 |
| US5370872A (en) | 1991-08-12 | 1994-12-06 | Swiss Serum And Vaccine Institute Berne | Escherichia coliO-polysaccharide-protein conjugate vaccine |
| US5593969A (en) | 1991-09-03 | 1997-01-14 | Igen Incorporated | Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors |
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| CN1326564C (zh) | 1997-04-01 | 2007-07-18 | 科里克萨有限公司 | 单磷酰基脂质a的水性免疫佐剂组合物 |
| US6500434B1 (en) | 1998-04-23 | 2002-12-31 | Medimmune, Inc. | Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections |
| US6858211B1 (en) | 1998-07-20 | 2005-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccines against Escherichia coli O157 infection |
| KR100629028B1 (ko) | 1998-10-16 | 2006-09-26 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 애쥬번트 시스템 및 백신 |
| EP1194563A1 (en) * | 1999-07-15 | 2002-04-10 | Medimmune, Inc. | Fimh adhesin-based vaccines |
| WO2001025254A2 (en) | 1999-10-04 | 2001-04-12 | University Of Maryland Biotechnology Institute | Novel adjuvant comprising a lipopolysaccharide antagonist |
| ES2309064T3 (es) | 2000-04-13 | 2008-12-16 | Corixa Corporation | Composiciones inmunoestimulantes que comprenden un fosfato de aminoalquil glucosaminida y qs-21. |
| AU2001271907A1 (en) | 2000-07-07 | 2002-01-21 | Medimmune, Inc. | FimH adhesin proteins and methods of use |
| WO2002015928A1 (en) | 2000-08-18 | 2002-02-28 | Medimmune, Inc. | METHOD OF ADMINISTERING FimH PROTEIN AS A VACCINE FOR URINARY TRACT INFECTIONS |
| US20030199071A1 (en) | 2000-12-08 | 2003-10-23 | Solomon Langermann | Mutant proteins, high potency inhibitory antibodies and fimch crystal structure |
| US6676958B2 (en) | 2001-06-19 | 2004-01-13 | Advanced Bioadjuvants, Llc | Adjuvant composition for mucosal and injection delivered vaccines |
| CN101019123A (zh) * | 2004-02-06 | 2007-08-15 | 科学与工业研究委员会 | 用于识别有治疗潜力的粘附素和粘附素样蛋白的计算方法 |
| CN103285392A (zh) | 2005-04-26 | 2013-09-11 | 卫材R&D管理株式会社 | 用于癌症免疫疗法的组合物和其用途 |
| ES2353814T3 (es) | 2005-05-11 | 2011-03-07 | Eth Zuerich | Proteinas n-glicosiladas recombinantes de celulas procariotas. |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| ES2536426T3 (es) | 2006-03-23 | 2015-05-25 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores |
| US8063063B2 (en) | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
| CN101983070B (zh) | 2008-02-20 | 2016-03-30 | 格林考瓦因有限公司 | 由来源于原核细胞的重组n-糖基化蛋白制备生物共轭物 |
| CA2764374C (en) | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
| ES2729967T3 (es) | 2012-02-07 | 2019-11-07 | Infectious Disease Res Inst | Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| US9415101B2 (en) | 2013-09-25 | 2016-08-16 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9149521B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9504743B2 (en) | 2013-09-25 | 2016-11-29 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US20150086592A1 (en) | 2013-09-25 | 2015-03-26 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9415097B2 (en) | 2013-09-25 | 2016-08-16 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9149522B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| WO2015124769A1 (en) | 2014-02-24 | 2015-08-27 | Glycovaxyn Ag | Novel polysaccharide and uses thereof |
| WO2016183501A1 (en) * | 2015-05-13 | 2016-11-17 | University Of Washington | Compositions and methods for treatment and prevention of uropathogenic e. coli infection |
| EA039065B1 (ru) | 2015-07-07 | 2021-11-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
| TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
| US11723985B2 (en) * | 2017-09-08 | 2023-08-15 | Cytoseek Limited | Protein delivery to membranes |
| WO2019175147A1 (en) * | 2018-03-12 | 2019-09-19 | Janssen Vaccines & Prevention B.V. | Vaccines against intra-abdominal infections |
| US20240027467A1 (en) * | 2019-12-20 | 2024-01-25 | Vib Vzw | Nanobody Exchange Chromatography |
| EP4461744A3 (en) | 2020-01-16 | 2025-01-08 | Janssen Pharmaceuticals, Inc. | Fimh mutant, compositions therewith and use thereof |
| KR20250007029A (ko) | 2021-01-12 | 2025-01-13 | 얀센 파마슈티칼즈, 인코포레이티드 | FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도 |
-
2022
- 2022-01-11 KR KR1020247041946A patent/KR20250007029A/ko active Pending
- 2022-01-11 MX MX2023008251A patent/MX2023008251A/es unknown
- 2022-01-11 KR KR1020237026809A patent/KR102746713B1/ko active Active
- 2022-01-11 US US17/573,249 patent/US11725028B2/en active Active
- 2022-01-11 EP EP22700099.9A patent/EP4277921A1/en active Pending
- 2022-01-11 CA CA3207841A patent/CA3207841A1/en active Pending
- 2022-01-11 IL IL303954A patent/IL303954B2/en unknown
- 2022-01-11 WO PCT/IB2022/050166 patent/WO2022153166A1/en not_active Ceased
- 2022-01-11 CN CN202280009667.0A patent/CN116888140A/zh active Pending
- 2022-01-11 AR ARP220100049A patent/AR124604A1/es unknown
- 2022-01-11 AU AU2022207740A patent/AU2022207740B2/en active Active
- 2022-01-11 JP JP2023541784A patent/JP7532672B2/ja active Active
- 2022-01-11 TW TW111101159A patent/TW202241929A/zh unknown
-
2023
- 2023-06-26 US US18/341,018 patent/US12297238B2/en active Active
-
2024
- 2024-04-22 JP JP2024068916A patent/JP2024109576A/ja active Pending
-
2025
- 2025-04-08 US US19/173,414 patent/US20250289854A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220220159A1 (en) | 2022-07-14 |
| IL303954A (en) | 2023-08-01 |
| IL303954B2 (en) | 2025-04-01 |
| MX2023008251A (es) | 2023-07-26 |
| TW202241929A (zh) | 2022-11-01 |
| EP4277921A1 (en) | 2023-11-22 |
| CN116888140A (zh) | 2023-10-13 |
| US20250289854A1 (en) | 2025-09-18 |
| WO2022153166A1 (en) | 2022-07-21 |
| AU2022207740A1 (en) | 2023-06-29 |
| KR20230125842A (ko) | 2023-08-29 |
| IL303954B1 (en) | 2024-12-01 |
| KR20250007029A (ko) | 2025-01-13 |
| JP2024109576A (ja) | 2024-08-14 |
| CA3207841A1 (en) | 2022-07-21 |
| US12297238B2 (en) | 2025-05-13 |
| AU2022207740B2 (en) | 2024-06-06 |
| JP7532672B2 (ja) | 2024-08-13 |
| AU2022207740A9 (en) | 2024-09-05 |
| US11725028B2 (en) | 2023-08-15 |
| US20230406890A1 (en) | 2023-12-21 |
| KR102746713B1 (ko) | 2024-12-24 |
| JP2024502854A (ja) | 2024-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124604A1 (es) | Mutantes de fimh, composiciones con los mismos y uso de los mismos | |
| AR121066A1 (es) | Mutante de fimh, composiciones que lo contienen y uso del mismo | |
| PE20231648A1 (es) | CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DIMERO DEL RECEPTOR DE INTERLEUCINA 2 byc Y CONJUGADOS CON UN POLIMERO HIDROSOLUBLE NO PEPTIDICO | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| MX2023008115A (es) | Terapia con receptores quiméricos. | |
| MX2020010075A (es) | Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos. | |
| CO2020013221A2 (es) | Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos | |
| BRPI0809926B8 (pt) | composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora | |
| AR091866A1 (es) | Analogos del glucagon | |
| ES2103295T3 (es) | Secuencia nucleotida codificante para una proteina de la membrana externa de neisseria meningitidis, y su utilizacion en la preparacion de vacunas. | |
| MX9205985A (es) | Epitopes de las celulas t de los alergenos principales del genero dermatophagoides y composiciones farmaceuticas que los contienen. | |
| BR112022020438A2 (pt) | Composições compreendendo três proteínas de fusão ospa para uso médico | |
| BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
| BR112013013548B8 (pt) | Proteína de fusão anticancerígena | |
| BR112022026580A2 (pt) | Composições e métodos para induzir uma resposta imune contra coronavírus | |
| CL2023003017A1 (es) | Composiciones y métodos para inhibir cetohexoquinasa (khk) | |
| BR112021023957A2 (pt) | Peptídeos | |
| AR115537A1 (es) | Terapia combinada con una vacuna neoantigénica | |
| MX2023008272A (es) | Vacunas contra el virus de la inmunodeficiencia humana (vih) y metodos de uso. | |
| PE20241621A1 (es) | Composiciones de polinucleotidos y sus usos | |
| DE60322559D1 (de) | Neue, mhc klasse ii assoziierte peptide | |
| Behera et al. | Biochemical analysis and antitumour effect of Abrus precatorius agglutinin derived peptides in Ehrlich's ascites and B16 melanoma mice tumour model | |
| AR102890A1 (es) | Polipéptidos que comprenden una secuencia de aminoácidos g3p de bacteriófago sin señal de glucosilación | |
| MX2019002321A (es) | Identificación de mutaciones en variantes de opsina de canal con sensibilidad a la luz mejorada y métodos de uso de estas. | |
| MX2021013018A (es) | Formulacion de arnm. |